About us
Pipeline
Target Markets
Our Technologies
Partnering
News, Media & Events
Investors
Careers
Contact
Home
News, Media & Events
Media Coverage
Neil Clark & Shaun Claydon of Destiny Pharma: Collaboration for NTCD-M3 worth up to $570m plus royalties – Vox Markets
Neil Clark & Shaun Claydon of Destiny Pharma: Collaboration for NTCD-M3 worth up to $570m plus royalties – Vox Markets